+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years - 90Years
All Genders
ID07250035

Evaluating Jiedu Huayu Oral Prescription for Treating Intracranial Hemorrhage Linked to Cerebral Amyloid Angiopathy A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Led by Beijing Tiantan Hospital · Updated on 2026-09-30

436

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying cerebral amyloid angiopathy CAA, a significant cause of primary cerebral hemorrhage, which is a serious cerebrovascular disease with high disability and mortality rates. The study focuses on patients with CAA-related intracranial hemorrhage, who have a high recurrence rate of vascular events and limited treatment options. The goal is to evaluate a combined traditional Chinese and Western medicine treatment to reduce vascular events and improve patient outcomes. Participants will receive either the Jiedu Huayu Oral Prescription or a placebo, in a randomized, double-blind, placebo-controlled trial conducted across multiple centers. The study includes patients within 7 days of onset of CAA-related intracranial hemorrhage. The effectiveness of the treatment will be measured by vascular event rates, hematoma expansion, liver and kidney function, and the impact on cognitive and neurological functions. Safety will be monitored through incidence rates and biological indicators. During the study, participants will be assessed at multiple time points up to one year after onset, including evaluations of vascular events, neurocognitive function, neurological recovery, and quality of life. Imaging and laboratory tests will support the evaluation of treatment effects and safety. The trial aims to provide new treatment options and improve prognosis for patients with CAA-related intracranial hemorrhage while reducing medical and social burdens.

CONDITIONS

Brief Title

Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Research Team

D

Dandan Wang Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here